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Abstract
Background:  RET/PTC (rearranged in transformation/papillary  thyroid carcinomas) gene
rearrangements are the most frequent genetic alterations identified in papillary thyroid carcinoma.
Although it has been established that RET/PTC kinase plays a crucial role in intracellular signaling
pathways that regulate cellular transformation, growth, and proliferation in thyroid epithelial cells,
the upstream signaling that leads to the activation of RET/PTC is largely unknown. Based on the
observation of high levels of PLD expression in human papillary thyroid cancer tissues, we
investigated whether PLD plays a role in the regulating the RET/PTC-induced STAT3 activation.
Methods: Cancer tissue samples were obtained from papillary thyroid cancer patients (n = 6). The
expression level of PLD was examined using immunohistochemistry and western blotting. Direct
interaction between RET/PTC and PLD was analyzed by co-immunoprecipitation assay. PLD
activity was assessed by measuring the formation of [3H]phosphatidylbutanol, the product of PLD-
mediated transphosphatidylation, in the presence of n-butanol. The transcriptional activity of
STAT3 was assessed by m67 luciferase reporter assay.
Results: In human papillary thyroid cancer, the expression levels of PLD2 protein were higher than
those in the corresponding paired normal tissues. PLD and RET/PTC could be co-
immunoprecipitated from cells where each protein was over-expressed. In addition, the activation
of PLD by pervanadate triggered phosphorylation of tyrosine 705 residue on STAT-3, and its
phosphorylation was dramatically higher in TPC-1 cells (from papillary carcinoma) that have an
endogenous RET/PTC1 than in ARO cells (from anaplastic carcinoma) without alteration of total
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STAT-3 expression. Moreover, the RET/PTC-mediated transcriptional activation of STAT-3 was
synergistically increased by over-expression of PLD, whereas the PLD activity as a lipid hydrolyzing
enzyme was not affected by RET/PTC.
Conclusion: These findings led us to suggest that the PLD synergistically functions to activate the
STAT3 signaling by interacting directly with the thyroid oncogenic kinase RET/PTC.
Background
Papillary thyroid carcinoma (PTC) is frequently associ-
ated with RET (rearranged in transformation) gene rear-
rangement that results in fusing the RET tyrosine kinase
domain to the N-terminal region of heterologous genes
[1]. Among human tumors, RET rearrangements are
restricted to the thyroid gland, where they are considered
specific for papillary carcinoma [2,3]. To date, 12 different
fusion partner genes are reported to form at least 17 differ-
ent RET hybrid oncogenes. The most prevalent variants of
these chimeric oncogenes are RET/PTC1 (60 to 70%) and
RET/PTC3 (20 to 30%) [1,3-5]. The rearrangements result
in ligand-independent activation of RET tyrosine kinase
which is considered crucial for activating the cellular sign-
aling pathways involved in transformation of thyroid
cells. Indeed, RET/PTC transforms thyroid follicular cells
in vitro [6], and the specific overexpression of RET/PTC1
or RET/PTC3 in the thyroid of transgenic mice leads to the
development of tumors that resemble PTC [7-9].
In recent years, extensive research on the RET/PTC signal-
ing pathway has greatly advanced our understanding of
the mechanisms of thyroid tumorigenesis. It has been
shown that the transforming potential of RET/PTC is
related to the activation of multiple signaling cascade and
tyrosine kinase [10]. As the chimeric forms of RET tyrosine
kinase are translated into fusion proteins, the protein-pro-
tein interaction motifs of amino terminal region allow
dimerizing interfaces, which then lead to RET autophos-
phorylation and constitutive kinase activity. Conse-
quently, when phosphorylated, it acts as a binding site for
several adaptors and signaling molecules, including Src
homology 2 domain containing (Shc), growth factor
receptor binding protein2 (Grb2), insulin receptor sub-
strate 1/2 and phospholipase Cγ [1]. This triggers a cyto-
plasmic signaling that leads to the activation of Ras/ERK
and phosphatidylinositol 3-kinase (PI-3K) signaling path-
ways [11]. In a recent experiment, the signal transducer
and activator of transcription-3 (STAT-3) has been identi-
fied as a direct substrate for RET/PTC tyrosine kinase in
thyroid cells. In fact, it has been shown that RET/PTC
associates with STAT-3 and activates it through the specific
phosphorylation of the tyrosine 705 residue, and thus
turns on the cyclin D1, vascular endothelial growth factor
(VEGF) and intracellular adhesion molecule 1 [12]. These
findings suggest that STAT3 activation by the RET/PTC
tyrosine kinase is one of the critical signaling pathways for
cellular transformation during the condition of thyroid
tumorigenesis.
Phospholipase D (PLD) family is a signal transduction-
activated enzyme, which is responsible for many cellular
signals during a variety of cellular processes, including
membrane trafficking, cytoskeletal reorganization, cell
proliferation, differentiation, survival and apoptosis [13].
Two isoforms of PLD, PLD1 and PLD2, have been studied
in mammalian cells [14,15], and they differ in the mech-
anism of activation and subcellular localization [14,16].
PLD1 has a low basal activity and is found throughout the
cells, but particularly in perinuclear, Golgi and heavy
membrane fractions [17,18]. In contrast, PLD2 has a high
basal activity and is localized mainly on the plasma mem-
brane [18]. Although PLD1 has likewise been implicated
in retrograde vesicle movement in the Golgi and receptor
endocytosis [16,19,20], both PLD1 and PLD2 have also
reported to provide a survival signal that overcomes cell
cycle arrest and apoptotic cell death [21]. Many studies
have shown that PLD activity is enhanced in response to
platelet-derived growth factor (PDGF) [22], epidermal
growth factor (EGF) [23], fibroblast growth factor (FGF)
[24], growth hormone and insulin-like growth factor 1
[25]. PLD activity is also elevated in the cells transformed
by a variety of transforming oncogenes and some human
cancers [21,26]. More importantly, it has been reported
that PLD not only suppresses apoptosis in the cells with
elevated tyrosine kinase activity but also cooperates with
tyrosine kinases to contribute to progressing to a malig-
nant phenotypes [27,28]. This suggests that the elevated
PLD activity may have a critical role for cell proliferation,
survival signaling, and tumor progression in cancers
where elevated tyrosine kinase expression is common.
Indeed, the elevated expression or activity of PLD has
been reported in breast cancer tissues and cell lines where
frequently there is the elevated expression of tyrosine
kinases such as the EGF receptor, c-Src and Her2/Neu
[29]. Consequent with this idea, we hypothesize that PLD
synergistically functions to activate STAT3 signaling by
directly interacting with thyroid oncogenic kinase RET/
PTC in the papillary thyroid cancer cells.
Methods
Tissue samples and preparation of homogenates
Tissue samples were obtained from sequential patients
during surgical operations for papillary thyroid cancers atBMC Cancer 2008, 8:144 http://www.biomedcentral.com/1471-2407/8/144
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Chungnam National University Hospital, Daejeon, Korea.
The study was approved by the hospital institutional
review board (approval number 07-04) according to the
Declaration of Helsinki, and the written informed consent
was obtained from each patient by research team prior to
surgery. After washing with cold saline, normal and can-
cerous tissues were immediately frozen in liquid nitrogen
and then stored at -70°C until analysis. Frozen tissues
were thawed and homogenized in 100 mM Tris-HCl (pH
8.0) and 1% Triton X-100. Tissue homogenates were cen-
trifuged at 1,500 × g for 15 min to remove debris. Follow-
ing clarification, the homogenates were centrifuged at
100,000 × g for 1 h at 4°C. Protein concentration of
homogenates was determined for each sample using the
Bradford method (Bio-Rad, Hercules, CA)
Cell culture and transfection
HEK293 cells, NIH 3T3 cells, human papillary thyroid
cancer cells (TPC1), which bears the RET/PTC1 rearrange-
ment, and human anaplastic thyroid cancer cells (ARO)
were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum, 2 mM
glutamine, 100 U/ml penicillin, and 100 µg/ml strepto-
mycin at 37°C with 5% CO2. The cells were transiently
transfected with the flag-PLD and RET/PTC expression
plasmids using lipofectAMINE PLUS (Invitrogen, San
Diego, CA) following the manufacturer's instructions.
Briefly, the plasmids were mixed with the Plus reagent and
then incubated with lipofectAMINE. The lipofectAMINE
Plus DNA complex was added to the cells and further
incubated for 3 h at 37°C. The control cells received the
lipofectAMINE PLUS alone. After incubation, the medium
was removed and replaced with fresh medium and cells
were maintained for additional 24 h.
PLD activity assay
PLD activity was assayed by measuring the formation of
phosphatidylbutanol (PtdBut), the product of PLD-medi-
ated transphosphatidylation, in the presence of 0.3% n-
butanol. TPC1 and ARO cells were loaded in complete
medium containing 1 µCi/ml of [3H]myristic acid for 3 h
at 37°C. Cells were then washed twice with phosphate-
buffered saline (PBS) and preequilibrated in serum-free
DMEM for 1 h and treated for the indicated concentra-
tions with pervanadate. For the final 10 min of preincuba-
tion, 0.3% n-butanol was added. Cells were then collected
and the lipids were extracted according to the method of
Lee [30]. Briefly, PtdBut was separated by thin layer chro-
matography (TLC) on silica gel 60A plates using a solvent
complex of ethylacetate/isooctane/acetic acid/water (110/
50/20/11, v/v). The region corresponding to PtdBut was
visualized by iodine vapor staining, scraped, and counted
by a liquid scintillation counter (Beckman LS 6500). Radi-
oactivity incorporated into total lipids was used to nor-
malize the results. The produced [3H]PtdBut by PLD
activity was expressed as a ratio of total lipid radioactivity
([3H]PtdBut/total lipid).
Western blot analysis
After treating with different reagents as described in the
Figure legends, cells were collected and lysed in M2 buffer
(20 mM Tris, pH 7.6, 0.5% NP-40, 250 mM NaCl, 3 mM
EDTA, 3 mM EGTA, 2 mM dithiothreitol, 0.5 mM PMSF,
20 mM β-glycerol phosphate, 1 mM sodium vanadate,
and 1 µg/ml leupeptin). Then the lysates were denatured
by boiling for 5 min in 1 × SDS-PAGE sample buffer,
resolved on sodium dodecyl sulfate-polyacrylamide gel
and blotted onto polyvinylidene difluoride membrane.
After blocking with 5% skim milk in PBS containing
0.05% tween-20, the membrane was probed with the rel-
evant antibodies and visualized by enhanced chemilumi-
nescence (Amersham, Arlington Heights, IL).
RT-PCR
Expression of RET/PTC in papillary thyroid cancer tissues
were analyzed by semiquantitative RT-PCR analysis. After
the total RNA was prepared using a TRIZOL reagent (Life
Technologies, Inc.), the oligo(dT)-primed cDNA was syn-
thesized using a RT-PCR kit (Stratagene, La Jolla CA). PCR
amplification was carried out using the primer pair spe-
cific to human RET/PTC1 (5'-GTCGGGGGGCATTGT-
CATCT-3' and 5'-AAGTTCTTCCGAGGGAATTC-3') and
human GAPDH (5'-GACCCCTTCATTGA CCTC-3' and 5'-
GCCATCCACAGTCTTCTG-3')
Immunoprecipitation assay
For immunoprecipitation assay, the cells were collected in
lysis buffer (50 mM HEPES at pH 7.6, 150 mM NaCl,
0.1% NP-40, 5 mM EDTA, 0.5 mM phenylmethyl sulfonyl
fluoride, 1 µg/ml leupeptin, 1 µg/ml aprotinin and 1 µg/
ml pepstatin) after treatments as described in the Figure
legends. The resulting cell lysates were spun at 15,000 × g
for 10 min at 4°C, and protein the concentration of the
supernatants were measured by Bradford method with a
bovine serum albumin as a standard. An equal amount of
cell lysates was precipitated with the relevant antibody (1
µg) against flag or RET and protein G-sepharose beads by
incubation at 4°C for 4 h to overnight. All the immuno-
precipitates were washed four times with lysis buffer,
boiled in SDS-PAGE sample buffer and resolved on 10%
polyacrylamide gel.
Immunohistochemistry
Expression of PLD was analyzed by immunohistochemis-
try (IHC) on paraffin-embedded tissue sections from six
thyroid cancer tissues. Three µm thick sections from the
paraffin blocks were used for IHC with rabbit EnVision-
HRP detection system (Dako, Crpinteria, CA, USA). The
anti-PLD antibody (Upstate, Lake Placid, NY) was used
for IHC. After deparaffinization and antigen retrieval by aBMC Cancer 2008, 8:144 http://www.biomedcentral.com/1471-2407/8/144
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pressure cooker in 10 mM sodium citrate buffer (pH 6.0)
at full power for 4 min, tissue sections were treated with
3% hydrogen peroxide for 10 min. The primary antibody
was diluted (1:50) with background reducing diluent
(Dako) and incubated for 30 min. The slides were then
incubated with the En Vision reagent for 30 min, and then
sequentially incubated with DAB chromogen for 5 min,
counterstained with Meyer's hematoxylin and mounted.
Careful rinses with several changes of TBS-0.3% tween
buffer were performed at each step. Negative control was
used using mouse IgG1 isotype control to exclude the pri-
mary antibody. Cytoplasmic staining was considered as
positive cells.
Luciferase assay
Firefly and Renilla luciferase activities were measured with
the Dual-Luciferase assay system. After transfection with
m67-Luc, pRL-SV40 that is encoding Renilla  luciferase,
STAT3, RET/PTC and PLD construct, the cells were lysed
and the luciferase assay was performed using a luciferase
assay kit (Promega Corp., Madison. WI). The data were
presented as fold inductions of the ratio of firefly per
Renilla luciferase activities of each sample.
Statistical analysis
Data are expressed as the mean ± SE from at least three
separate experiments performed in triplicate. The differ-
ences between groups were analyzed using a Student' s t-
test, and P values < 0.05 were considered statistically sig-
nificant. Statistical analyses were carried out using Statisti-
cal Package for Social Science software program (version
11.0; SPSS Inc. IL.).
Results and Discussion
PLD2 level is increased in human papillary thyroid cancer 
tissues
Since PLD contributes to the progression to a malignant
phenotype in the cells with elevated tyrosine kinase activ-
ity [27], the level of PLD expression may have a close rela-
tionship with the development of papillary thyroid
cancers. Therefore, the expression levels of PLD were com-
pared by Western blotting in normal and cancerous tis-
sues from 6 patients who underwent surgery for papillary
thyroid cancer. As shown in Figure 1A, we detected the
enhanced expression of PLD2 in 4 out of the 6 papillary
thyroid cancer tissues, though PLD1 which is predicted to
be 116 kDa, was not detected in the same blot. PLD2 was
low or nondetectable in normal thyroid tissues, suggest-
ing that the enhanced PLD expression, especially in PLD2,
may play a role in controlling the papillary thyroid cancer
development. To confirm this observation, we performed
immunohistochemistry on the same tissues. As expected,
the papillary thyroid cancer tissues expressed PLD2 at a
dramatically higher level than the normal tissue (Fig. 1B).
To ensure that RET/PTC is indeed express in papillary thy-
roid cancer tissues, we confirmed the expression of RET/
PTC-1 by semiquantitative RT-PCR in the cancerous tis-
sues but not in normal thyroid tissues (Fig. 1C). The
mRNA expression of papillary (TPC-1) thyroid cancer cell
lines, which harbor RET/PTC1 was served as a control.
PLDs physically interact with RET/PTC1 and 
synergistically enhance in STAT3 phosphorylation induced 
by RET/PTC tyrosine kinase
Results of recent studies have indicated that the elevated
expression of PLD cooperates with non-receptor tyrosine
kinase, such as c-Src to induce the cellular proliferation
through direct interaction [28]. Since RET/PTC tyrosine
kinase is linked to the specific signaling pathway in papil-
lary thyroid cancer, we examined whether PLD isotypes
could associate with the RET/PTC. Cells were cotrans-
fected with PLD1 or PLD2 plus RET/PTC1 in HEK293
cells, and the cell lysates were immunoprecipitated with
antibodies against RET or Flag. Coimmunoprecipitation
assays indicated that both PLD1 and PLD2 associated
with RET/PTC1 to a similar extent when the cell lysates
were immunoprecipitated with antibodies against RET or
Flag (Fig. 2A). Importantly, endogenous PLD2 was found
to interact consistently with RET/PTC1 in TPC-1 cells,
where RET/PTC1 protein was overexpressed (Fig. 2B).
Another oncogenic form, RET/PTC3, also interacted with
PLD1 or PLD2 (data not shown), suggesting that the inter-
action of PLD and RET/PTC takes place presumably
through catalytic domain of RET. In previous studies, it
has been shown that the enzymatic activity of PLD as a
lipid hydrolytic enzyme is not be strictly required for PLD
function to amplify the mitogenic signal [28,31]. There-
fore, we next investigated whether the lipase activity of
PLD is required for interaction with RET/PTC-1. The
lipase-inactive mutant of PLD2, PLD2-K758R (KRM) also
bound to RET/PTC1 as like the wild-type PLD2 (Fig. 2C),
indicating that the lipase activity of PLD2 is not required
for this interaction.
It has been well established that TPC-1 cell lines has
cytogeneticallay genomic changes characterized by trans-
location involving chromosome 1, 10 and 21 (RET/PTC
rearrangement) and therefore this cell atypically harbors
RET/PTC1 among the thyroid epithelial cancer cells [32].
To address the biological relevance of high PLD expres-
sion and RET/PTC in papillary thyroid cancers, we com-
pared the activity of PLD and the extent of pervanadate-
induced STAT3 phosphorylation in human anaplastic
(ARO) and papillary (TPC-1) thyroid cancer cell lines. The
basal activity and pervanadate-induced activation of PLD
were significantly higher in TPC-1 cells than in ARO cells
(Fig. 3A). Furthermore, we also observed the enhanced
expression of PLD2 in TPC-1 cells compared to that in
ARO cells (Fig. 3B, third panel). This is consistent with the
results shown earlier that PLD2 level is increased in papil-BMC Cancer 2008, 8:144 http://www.biomedcentral.com/1471-2407/8/144
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Overexpression of PLD2 in papillary thyroid tumor tissue Figure 1
Overexpression of PLD2 in papillary thyroid tumor tissue. (A) Normal and cancer tissue extracts from 6 patients who 
underwent surgery for malignant papillary thyroid cancer were prepared as described in Methods. The tissue extracts and 
transfectant controls of PLD1/PLD2 were applied to SDS-PAGE for Western blotting with antibodies directed against PLD and 
β-actin. (B) Immunohistochemistry of PLD in normal and cancerous tissue. PLD2 was highly expressed in papillary thyroid can-
cer tissue (B) compared to faintly stained normal thyroid tissue (A). (C, D) Negative isotype control with preimmune mouse 
IgG1. Original magnification, 100×. (C) Expression of RET/PTC-1 in malignant papillary thyroid cancer tissue. After the normal 
and cancer tissues were lysed and the total RNA was isolated, RT-PCR was performed with the primers specific to the human 
RET/PTC1 and GAPDH. After the PCR amplification, the products were separated by agarose gel electrophoresis and visual-
ized using ethidium bromide staining. The results are representative of three independent experiments.
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Physical association between PLD and RET/PTC1 Figure 2
Physical association between PLD and RET/PTC1. (A) HEK293 cells were transfected with flag-tagged-PLD1 or -PLD2 
and RET/PTC1 expression plasmids. After 24 h transfection, whole cell lysates were immunoprecipitated with anti-RET (upper 
panel) or anti-flag (lower panel) antibodies, and then immunoprecipitants were analyzed by Western blotting with anti-flag or 
anti-RET antibodies. The efficiency of immune-precipitant was measured with anti-RET and anti-flag antibodies (each bottom 
panel). (B) TPC-1 cells were transfected with RET/PTC1 expression plasmid, and whole cell lysate was immnunoprecipitated 
with antibodies directed against RET and normal IgG. Immunoprecipitates were analyzed by Western blotting with anti-PLD 
antibody (upper panel). The efficiency of immune-precipitant was measured with anti-RET antibody (bottom panel). One per-
cent of cell extracts from sample was used as a control of protein input. (C) HEK293 cells were transfected with various com-
binations of plasmids encoding an empty vector, RET/PTC1 plus either flag-tagged wild-type (wt)- or lipase inactive mutant 
(KRM)- PLD2. Cell lysates were immunoprecipitated with anti-flag antibody, and then immunoprecipitants were analyzed by 
Western blotting with anti-RET antibody (upper panel). The efficiency of immune-precipitant was measured with anti-flag anti-
body (bottom panel).
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PLD synergistically enhanced in STAT3 phosphorylation induced by RET/PTC tyrosine kinase Figure 3
PLD synergistically enhanced in STAT3 phosphorylation induced by RET/PTC tyrosine kinase. (A) ARO and 
TPC-1 cells were prelabeled with [3H]-myristic acid for 3 h and then treated with the various concentrations of pervanadate 
for 30 min as indicated, 10 min before the end of the treatment, cells were incubated with 0.3% n-butanol. Radioactivity incor-
porated into PtdBut was measured as described in Methods. Each bar shows mean ± SE of at least of three independent exper-
iments. * P < 0.05, when compared with none-treated ARO cells. # P < 0.05, when compared with pervanadate-treated ARO 
cells. (B) ARO and TPC-1 cells were treated with the various concentrations of pervanadate for 30 min as indicated. Whole 
cell lysates were analyzed by SDS-PAGE and Western blotting with antibodies against phosphorylated STAT3 (Y705), RET and 
PLD2. To confirm equal amounts of protein were loaded, the blots were reproved using an antibody against total STAT3 and 
β-actin. (C) TPC-1 cells were pretreated with n-butanol for indicated concentrations or 2% t-butanol and then treated with 10 
µM pervanadate for 30 min. Cell extracts were analyzed by SDS-PAGE and Western blotting with antibodies against 
phosphoY705-STAT3 and STAT3. (D, E) ARO cells were transiently transfected with mock vector and RET/PTC1 (D) or RET/
PTC3 (E) expression plasmids. At 24 h transfection, the cells were untreated or treated with 50 µM pervanadate for 30 min, 
and then total cell lysates were prepared and blotted with anti-phosphoY705-STAT3, anti-STAT3 and anti-RET antibodies. The 
figure is representative of at least three separate experiments.
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lary thyroid cancer tissue (Figs. 1A and 1B). Previously, it
has been indicated that STAT3 is a direct substrate of RET/
PTC tyrosine kinase and that the phosphorylation of tyro-
sine (Y) 705 in STAT3 by RET/PTC is critical for the RET/
PTC-mediated transformation process [12]. More impor-
tantly, under these conditions, the immunoblotting with
the antibody specific to phosphorylated Y705 of STAT3
showed that the extent of pervanadate-induced STAT3
phosphorylation was also much higher in TPC-1 cells,
without alteration of total STAT-3 expression (Fig. 3B, first
and second panel). To ensure that the expression of RET/
PTC1 is indeed defective in ARO cells, the cell lysates
obtained from ARO cell and TPC1 cells were immunob-
lotted with antibody against RET/PTC1 and actin (Fig. 3B,
fourth and bottom panel). Furthermore, when TPC-1 cells
were pretreated with the PLD-specific inhibitor n-butanol,
pervanadate-induced STAT3 phosphorylation was
decreased, in a dose-dependent manner (Fig. 3C), indicat-
ing that pervanadate-induced STAT3 phosphorylation is
indeed mediated by PLD in TPC-1 cells.
To strengthen our findings, ARO cells were transfected
with pCMV-track-RET/PTC or control pCMV-track, and
subsequently treated with pervanadate to induce PLD acti-
vation. We detected the Y705 phosphorylation of STAT3
after transfection with RET/PTC1 (Fig. 3D) and RET/PTC3
(Fig. 3E), which is consistent with a previous report [12].
As a control, the cells transfected with mock vector did not
show Y705 phosphorylation of STAT3. Furthermore, we
also found that the pervanadate treatment resulted in a
dramatically higher level of Y705 phosphorylation of
STAT3 under overexpression conditions of RET/PTC1 or
RET/PTC3 in ARO cells (Fig. 3D and 3E). These data pro-
vide additional evidence that the activation of PLD
enhanced by pervanadate contributes to RET/PTC-medi-
ated STAT3 phosphorylation in thyroid epithelial cells.
RET/PTC enhances tyrosine phosphorylation of PLD2, but 
it is not necessary for functional PLD activity
The tyrosine kinase activity of RET/PTC is a crucial for its
oncogenic potential and for activation of the intracellular
signaling pathways involved in transformation [33]. Since
we found the physical interaction between PLD and RET/
PTC (Fig. 2), we examined whether RET/PTC tyrosine
kinase is capable of phosphorylating PLD. Immunopre-
cipitation assays were performed with Flag-tagged PLD2
in HEK293 cells cotransfected with RET/PTC1 and/or
Flag-PLD2, and an immunoblot analysis was conducted
with the antiphosphotyrosine antibody, 4G10. As shown
in the upper panel of Figure 4A, we found the tyrosine
phosphorylation of PLD2 in the cells cotransfected with
RET/PTC1 whereas the minimal basal tyrosine phosphor-
ylated protein was detected in the cells transfected with
mock vector. Furthermore, treatment with pervanadate, a
PLD activator, also induced the tyrosine phosphorylation
of PLD2, and the prevanadate-induced tyrosine phospho-
rylation was enhanced under the RET/PTC1 overexpres-
sion condition, suggesting that PLD2 is tyrosine
phosphoylated by the expression of RET/PTC tyrosine
kinase. To ensure that the same amount of PLD2 was pre-
cipitated in each sample, PLD2 levels in the immunopre-
cipitate were measured (Fig. 4A, lower panel).
Next, we investigated whether the tyrosine phosphoryla-
tion of PLD by RET/PTC has any effect on its phopholi-
pase activity. RET/PTC1 was ectopically expressed in
NIH3T3 cells, and in vivo PLD activity was measured fol-
lowing the pervanadate treatment. Unexpectedly, the per-
vanadate-induced PLD activity in the cells transfected
with RET/PTC1 was similar to that in the cells transfected
with mock vector (Fig. 4B). Transient transfection of RET/
PTC3 also did not affect the PLD activity (data not
shown). These results suggest that the tyrosine phosphor-
ylation of PLD by RET/PTC does not increase the PLD
phospholipase activity. However, the biological signifi-
cance of tyrosine phosphorylation of PLD enhanced by
RET/PTC still remains to be determined, because the PLD
enzyme activity has not been correlated with its phospho-
rylation level in this study. Recently, it has been reported
that tyrosine phosphorylation on PLD contributes to the
cellular proliferation through mitogenic signaling path-
ways [28,34]. Therefore one can speculate that, in case of
formation of binding complex between PLD2 and RET/
PTC, tyrosine phosphorylation of PLD2 by RET/PTC
might be involved in the potentiation of RET/PTC-medi-
ated STAT3 to amplify the mitogenic signal in papillary
thyroid tumor.
PLD enhances RET/PTC-dependent STAT3 transcriptional 
activity
In our experiments, we demonstrated that PLD synergisti-
cally increases the STAT3 phosphorylation induced by
RET/PTC tyrosine kinase, as measured by enhance Y705
phosphorylation of STAT3. Y705 phosphorylation of
STAT3 is known to be important for the dimerization,
translocation and transcriptional activation of STAT3
[35]. To determine whether the RET/PTC-mediated STAT3
phosphorylation enhanced by PLD could activate the
STAT3 transcriptional activities, we co-transfected the cells
with plasmids expressing RET/PTC and m67-luciferase
reporter construct containing multimerized STAT3-spe-
cific binding sites in HEK293 cells. As expected, the tran-
scriptional activity of STAT3 increased up to 20-fold in the
cells transfected with RET/PTC1 and RET/PTC3 (Fig. 5).
These observations were also confirmed in ARO cells,
even though the extent of fold activation was lesser than
in HEK293 cells because of a lower transfection efficiency
(data not shown). This indicates that the activation of
STAT3 can be monitored in transiently transfected cells
with the m67-luciferase reporter plasmid. Next, the abilityBMC Cancer 2008, 8:144 http://www.biomedcentral.com/1471-2407/8/144
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of PLD to regulate the activation of STAT3 was examined
in transiently transfected HEK293 cells expressing the
m67-luciferase reporter in the absence or presence of plas-
mids expressing Flag-tagged PLD2. Consistent with the
results described above (Fig. 3B, 3D and 3E), the expres-
sion of PLD2 synergistically enhanced RET/PTC1- or RET/
PTC3-depedent activation of STAT3. Furthermore, the
expression of the lipase inactive mutant PLD2 (KRM)
enhanced STAT3 activity to a similar extent than did wild-
type PLD2 (Fig. 5), which suggest that the lipase activity of
PLD2 is unlikely to be involved in RET/PTC-mediated
STAT3 activation. These findings led us to conclude that
the PLD enhance RET/PTC-mediated STAT3 phosphoryla-
tion resulting in the transcriptional activation of STAT3.
In the present study, we hypothesized that the elevated
expression of PLD might have a role to trigger a cytoplas-
mic signaling initiated by a protein tyrosine kinase RET/
PTC in papillary thyroid cancer. However, we did not
observe the direct evidence of the correlation between ele-
vated expression of PLD and thyroid epithelial growth/
differentiation. This could be explained as like that only
PLD may be not enough for thyroid tumorigenesis but
necessary. Other factors, such as environmental condi-
tion, genetic alterations, or hormonal effects may cooper-
atively responsible for cellular proliferation or
differentiation in thyroid epithelial cancer cells.
RET/PTC enhances tyrosine phosphorylation of PLD2, but it  does not affect the enzyme activity of PLD Figure 4
RET/PTC enhances tyrosine phosphorylation of 
PLD2, but it does not affect the enzyme activity of 
PLD. (A) HEK293 cells were transiently transfected with 
mock vector, flag-PLD2, RET/PTC1 expression plasmids, 
treated with pervanadate (50 µM) for 30 min, and subjected 
to immunoprecipitation with anti-flag antibody. Immunopre-
cipitate was analyzed by Western blotting with anti-phospho-
tyrosine specific antibody (4G10), and the efficiency of 
immunoprecipitation was measured with anti-PLD2 antibody. 
(B) NIH3T3 cells were transiently transfected with mock 
vector and RET/PTC1 expression plasmids, treated with per-
vanadate (50 µM) for 30 min. PLD activity was measured as 
described in the legend of Fig. 3A. Radioactivity of PtdBut 
was expressed in percent of radioactivity of total phospholip-
ids. * P < 0.05, when compared with empty vector trans-
fected group. Each bar shows mean ± SE of at least of three 
independent experiments.
A
0
0.002
0.004
0.006
0.008
- pervanadate
vector
RET/PTC1
B
p-Y-PLD2
PLD2
IP : flag
–+–+ P.V.
flag-PLD2 ++++
RET/PTC1 ––++
P
t
d
B
u
t
/
t
o
t
a
l
 
l
i
p
i
d
(
%
 
o
f
 
t
o
t
a
l
 
l
i
p
i
d
)
PLD synergistically enhances RET/PTC-mediated transcrip- tional activation of STAT3 Figure 5
PLD synergistically enhances RET/PTC-mediated 
transcriptional activation of STAT3. HEK293 cells were 
transfected with various combinations of plasmids encoding 
an empty vector, STAT3, RET/PTC1, RET/PTC3, flag-tagged 
wild-type (wt)- or lipase inactive mutant (KRM)- PLD2 and 
m67 luciferase reporter plasmid. After 24 h transfection, the 
cells were lysed and the luciferase activities were measured 
as described in Methods, and the activity of each sample was 
normalized according to Renilla luciferase activity (upper 
panel). Results show mean ± SE of at least of three independ-
ent experiments. * P < 0.05, when compared with STAT3 
alone-expressed group. # P < 0.05, when compared with 
STAT3 and RET/PTC1- or RET/PTC3-expressed group. To 
confirm the expression level of each plasmid in transfected 
cells, the total cell lysates were analyzed by SDS-PAGE and 
Western blotting with antibodies against flag and RET (lower 
panel).
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Conclusion
In summary, this study shows that the elevated expression
of PLD in papillary thyroid cancers plays a synergistic role
in the transcriptional activation of STAT3 by interacting
with RET/PTC. Thus, our findings offer a significant
advance in understanding the cross talk between PLD and
thyroid oncogenic kinase RET/PTC during the papillary
thyroid tumorigenesis.
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